Showing results (91-100 of 192) with videos related to
Sort By:
Pageof 20
Leukemia Research|July 26, 2011
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.Haematologica|August 30, 2012
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndromeChristopher P Venner, Joanna Wegrzyn Woltosz, Thomas J Nevill, et al.Leukemia Research|February 19, 2013
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLionel Adès, Mikkael A Sekeres, Alice Wolfromm, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2012
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndromeAdam W Mailloux, Chiharu Sugimori, Rami S Komrokji, et al.Leukemia Research|January 22, 2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification modelsVu H Duong, Jeffrey E Lancet, Ezzideen Alrawi, et al.Annals of Hematology|November 24, 2017
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromesVu H Duong, Eric Padron, Najla H Al Ali, et al.British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2010
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Alan F List, David Cuthbertson, et al.Pageof 20